Epidemiology and treatment patterns of idiopathic multicentric Castleman disease in the era of IL-6–directed therapy

por Mukherjee, Sudipto, Martin, Rabecka, Sande, Brenda, Paige, Jeremy S., Fajgenbaum, David C.
Publicado 2022

Siltuximab is associated with improved progression-free survival in idiopathic multicentric Castleman disease

por van Rhee, Frits, Rosenthal, Adam, Kanhai, Karan, Martin, Rabecka, Nishimura, Katherine, Hoering, Antje, Fajgenbaum, David C.
Publicado 2022

Organ dysfunction, thrombotic events and malignancies in patients with idiopathic multicentric castleman disease: a population-level US health claims analysis

por Mukherjee, Sudipto, Kanhai, Karan, Kauffman, David, Martin, Rabecka, Paige, Jeremy S., Ghosh, Anirvan, Kannan, Hannah, Shupo, Francis, Fajgenbaum, David C.
Publicado 2022

Correction to: Organ dysfunction, thrombotic events, and malignancies in patients with idiopathic multicentric Castleman disease: a population-level US health claims analysis

por Mukherjee, Sudipto, Kanhai, Karan, Kauffman, David, Martin, Rabecka, Paige, Jeremy S., Ghosh, Anirvan, Kannan, Hannah, Shupo, Francis, Fajgenbaum, David C.
Publicado 2022